Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH
Go back to Altimmune Initiates PERFORMA Phase 3 Trial of Pemvidutide in Patients with MASH| iShares Diversified Alternatives Trust (NASDAQ: ALT) | Delayed: 3.37 +0.10 (3.06%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.27 | 52 Week High | $54.24 | |||
| Open | $3.33 | 52 Week Low | $48.35 | |||
| Day High | $3.39 | P/E | N/A | |||
| Day Low | $3.30 | EPS | $0.00 | |||
| Volume | 460,879 | |||||
